![]() |
市場調查報告書
商品編碼
2024834
左心耳封堵器市場報告:按產品、最終用戶和地區分類(2026-2034 年)Left Atrial Appendage Closure Devices Market Report by Product (Endocardial LAA Devices, Epicardial LAA Devices), End User (Hospitals, Ambulatory Surgery Centers, and Others), and Region 2026-2034 |
||||||
2025年,全球左心耳封堵器市場規模達20億美元。預計到2034年將達到73億美元,2026年至2034年的複合年成長率為14.91%。心房顫動(AFib)盛行率的上升、易患心血管疾病(CVD)的老年人口不斷成長以及產品的持續進步和創新是推動市場成長的主要因素。
左心耳封堵器(LAAC)是一種植入心臟的醫療設備,用於降低非瓣膜性心房顫動(AFib)患者的中風風險。左心耳(LAA)是心臟心肌壁上的小囊狀結構,容易形成血栓,可能導致心房顫動患者發生中風。 LAAC裝置旨在永久封鎖左心耳,防止血栓形成,降低中風風險。該裝置通常透過微創手術植入,一般只需在手臂或鼠蹊部做一個小切口即可插入導管。對於無法服用抗凝血藥物或服用此類藥物出血併發症較高的心房顫動患者,LAAC裝置應用廣泛。
心房顫動(心房顫動)盛行率的上升,主要歸因於普遍存在的不健康飲食習慣、吸菸、飲酒和久坐的生活方式,是推動全球市場成長的主要因素。此外,老年人口的增加,尤其是易患心血管疾病(CVD)的老年人口,以及消費者對心房顫動相關風險和併發症日益成長的關注,還有人們對替代治療方法方案認知的提高,都在促進市場成長。同時,封堵器械在產品安全性和有效性方面的顯著技術進步,以及致力於開發微創封堵器械以縮短恢復時間、提高病患舒適度,也為市場創造了盈利的成長機會。此外,電生理介入治療的出現,以及介入治療和診斷流程的顯著改進,也促進了市場成長。最後,醫療基礎設施的快速擴張、醫療服務可及性的提高、微創封堵器械的日益普及、各國政府開展的眾多宣傳宣傳活動以及醫保報銷政策的製定,都進一步推動了市場擴張。此外,旨在進行產品創新的廣泛研發活動、核准的心房介入產品數量的增加、臨床試驗的增加以及機器人輔助封堵裝置等新技術的採用,都對市場成長產生了積極影響。
The global left atrial appendage closure devices market size reached USD 2.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 7.3 Billion by 2034, exhibiting a growth rate (CAGR) of 14.91% during 2026-2034. The escalating prevalence of atrial fibrillation (AFib), the growing geriatric population prone to cardiovascular disorders (CVDs), and ongoing product advancements and innovations represent some of the key factors driving the market.
Left atrial appendage closure devices (LAAC) are medical devices that are implanted in the heart to lower the risk of stroke in patients with non-valvular atrial fibrillation (AFib). The left atrial appendage (LAA) is a small pouch-like structure located in the muscle wall of the heart, which can be a source of blood clots, leading to stroke in AFib patients. LAAC devices are designed to permanently close off the LAA to prevent the formation of blood clots and reduce the risk of stroke. They are implanted via minimally invasive (MI) procedures, typically using a catheter that is inserted through a small incision placed in the arm or groin region. These devices are widely popular among AFib patients who cannot take anticoagulant medications or are at high risk of bleeding complications from these medications.
The rising prevalence of AFib, on account of the widespread adoption of unhealthy eating habits, smoking, drinking, and sedentary lifestyles, is primarily driving the global market growth. Besides this, the growing geriatric population prone to cardiovascular disorders (CVDs), the escalating consumer concerns regarding risks and complications associated with AFib, and the expanding awareness about the availability of alternative treatment options are impelling the market growth. Moreover, significant technological advancements in closure devices in terms of the safety and efficacy of the product and the intensive emphasis on developing minimally invasive closure devices to reduce recovery time and improve patient comfort are presenting remunerative growth opportunities for the market. Concurrent with this, the advent of electrophysiology procedures, combined with considerable improvements in interventional treatments and the diagnosis pathway, is contributing to the market growth. In addition to this, rapid expansion in the healthcare infrastructure, better access to healthcare services, the surging popularity of minimally invasive closure devices, the launch of numerous awareness campaigns by governments of various countries, and the availability of reimbursement policies are aiding in market expansion. Furthermore, extensive research and development (R&D) activities for product innovation, a rising number of atrial intervention product approvals, an increasing number of clinical trials, and the adoption of new technologies, such as robotic-assisted closure devices, are positively impacting the market growth.
The publisher provides an analysis of the key trends in each segment of the global left atrial appendage closure devices market, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on product, and end user.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for left atrial appendage closure devices. Some of the factors driving the North America left atrial appendage closure devices market included a growing number of atrial fibrillation (Afib) cases, a rise in the geriatric population, and innovative technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global left atrial appendage closure devices market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, AtriCure Inc., Boston Scientific Corporation, Cardia Inc., Lepu Medical Technology (Beijing) Co. Ltd., LifeTech Scientific, etc.